Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (61-70 of 267) with videos related to

Pageof 27
Sort By:
The Oncologist|April 2, 2008
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?Mateya Trinkaus, Sheray Chin, Wendy Wolfman, et al.
The Lancet. Oncology|November 1, 2005
Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction modelGeorge Dranitsaris, Mark Clemons, Sunil Verma, et al.
Nature Reviews. Clinical Oncology|April 1, 2010
Medical oncology: Zoledronic acid for breast cancer therapy-induced bone lossEitan Amir, Alberto Ocaña, Bostjan Seruga, et al.
The Oncologist|January 21, 2015
Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic reviewCarmel Jacobs, Brian Hutton, Terry Ng, et al.
The Lancet. Oncology|October 7, 2004
Assessment of therapeutic response in patients with metastatic bone diseaseAndrew Clamp, Sarah Danson, Huy Nguyen, et al.
Cancer Treatment Reviews|October 8, 2016
Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trialsNathalie LeVasseur, Mark Clemons, Brian Hutton, et al.
Breast Cancer Research and Treatment|March 21, 2008
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?Philippe L Bedard, Orit C Freedman, Anthony Howell, et al.
Journal of Geriatric Oncology|August 18, 2015
Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and olderShelly Sud, Pamela Lai, Tinghua Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2009
Prevention and management of bone metastases in lung cancer: a reviewHamed Al Husaini, Paul Wheatley-Price, Mark Clemons, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 27, 2021
Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomitingMashari Jemaan Alzahrani, George Dranitsaris, Marta Sienkiewicz, et al.
Pageof 27

Showing results (61-70 of 267) with videos related to

Sort By:
Pageof 27
The Oncologist|April 2, 2008
Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?Mateya Trinkaus, Sheray Chin, Wendy Wolfman, et al.
The Lancet. Oncology|November 1, 2005
Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction modelGeorge Dranitsaris, Mark Clemons, Sunil Verma, et al.
Nature Reviews. Clinical Oncology|April 1, 2010
Medical oncology: Zoledronic acid for breast cancer therapy-induced bone lossEitan Amir, Alberto Ocaña, Bostjan Seruga, et al.
The Oncologist|January 21, 2015
Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic reviewCarmel Jacobs, Brian Hutton, Terry Ng, et al.
The Lancet. Oncology|October 7, 2004
Assessment of therapeutic response in patients with metastatic bone diseaseAndrew Clamp, Sarah Danson, Huy Nguyen, et al.
Cancer Treatment Reviews|October 8, 2016
Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trialsNathalie LeVasseur, Mark Clemons, Brian Hutton, et al.
Breast Cancer Research and Treatment|March 21, 2008
Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?Philippe L Bedard, Orit C Freedman, Anthony Howell, et al.
Journal of Geriatric Oncology|August 18, 2015
Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and olderShelly Sud, Pamela Lai, Tinghua Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2009
Prevention and management of bone metastases in lung cancer: a reviewHamed Al Husaini, Paul Wheatley-Price, Mark Clemons, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 27, 2021
Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomitingMashari Jemaan Alzahrani, George Dranitsaris, Marta Sienkiewicz, et al.
Pageof 27